Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins.
Wei WQ, Li X, Feng Q, Kubo M, Kullo IJ, Peissig PL, Karlson EW, Jarvik GP, Lee MTM, Shang N, Larson EA, Edwards T, Shaffer CM, Mosley JD, Maeda S, Horikoshi M, Ritchie M, Williams MS, Larson EB, Crosslin DR, Bland ST, Pacheco JA, Rasmussen-Torvik LJ, Cronkite D, Hripcsak G, Cox NJ, Wilke RA, Stein CM, Rotter JI, Momozawa Y, Roden DM, Krauss RM, Denny JC. Wei WQ, et al. Circulation. 2018 Oct 23;138(17):1839-1849. doi: 10.1161/CIRCULATIONAHA.117.031356. Circulation. 2018. PMID: 29703846 Free PMC article.
The genetic determinants of this residual cardiovascular risk remain unknown. METHODS: We performed a 2-stage genome-wide association study of CHD events during statin therapy. ...A phenome-wide association study supported the effect of t …
The genetic determinants of this residual cardiovascular risk remain unknown. METHODS: We performed a 2-stage genome-wi …
Lipoprotein (a): When to Measure and How to Treat?
Rhainds D, Brodeur MR, Tardif JC. Rhainds D, et al. Curr Atheroscler Rep. 2021 Jul 8;23(9):51. doi: 10.1007/s11883-021-00951-2. Curr Atheroscler Rep. 2021. PMID: 34235598 Review.
It contributes to residual CV risk in patients receiving standard-of-care LDL-lowering therapy. Plasma Lp(a) levels present a skewed distribution towards higher values and vary widely between individuals and according to ethnic background due to geneti …
It contributes to residual CV risk in patients receiving standard-of-care LDL-lowering therapy. Plasma Lp(a) lev …
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.
Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Burgess S, et al. JAMA Cardiol. 2018 Jul 1;3(7):619-627. doi: 10.1001/jamacardio.2018.1470. JAMA Cardiol. 2018. PMID: 29926099 Free PMC article.
EXPOSURES: Genetic LPA score and plasma Lp(a) mass concentration. MAIN OUTCOMES AND MEASURES: Coronary heart disease. ...Thus, a 101.5-mg/dL change (95% CI, 71.0-137.0) in Lp(a) concentration had the same association with CHD risk as a 38.67-mg/ …
EXPOSURES: Genetic LPA score and plasma Lp(a) mass concentration. MAIN OUTCOMES AND MEASURES: Coronary heart disease. . …